EXTON, Pa. — November 11, 2014 — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the NovaGuard SA (Staked-needle Automatic) safety system has received 510(k) clearance from the United States Food and Drug Administration. The NovaGuard SA safety system helps reduce the risk of needlestick injuries by shielding the exposed needle of a prefilled syringe after use.
The World Health Organization (WHO) estimates that each year healthcare workers incur two million accidental needlestick injuries that may result in infections with hepatitis B and C, HIV and other diseases. Acknowledging the public health threat, the WHO, the European Union, the Occupational Safety and Health Administration and other leading health organizations have developed guidelines focused onneedle safety and recommending the use of safety-engineered devices to reduce sharps injuries.
"With increased global emphasis on preventing the spread of bloodborne infectious diseases, there is a need to develop and implement safer systems and practices in healthcare facilities worldwide. This includes adopting devices that can help reduce the risk of infection caused by needlestick," said Graham Reynolds, Vice President, Marketing and Innovation, West Pharmaceutical Services. "West has deep expertise in needlestick prevention and a portfolio of offerings that enable safe and effective drug administration. It's our hope that the NovaGuard SA safety system is used as a cost-effective solution to help improve needle safety."
Injectable drug delivery systems that incorporate a safety mechanism can significantly reduce the risk of accidental needlestick injuries. The NovaGuard SA safety system helps protect patients and healthcare workers by shielding a syringe's exposed needle once activated. The NovaGuard SA safety system is suitable for prefilled ISO standard glass syringes and provides a tamper-evident needleshield feature and a safety mechanism which helps to prevent pre-activation of the system. It is part of West's NovaGuard family of syringe safety technology offerings.
West has increased its manufacturing capacity at its facility in France, where more than 1.5 billion similar safety systems have already been produced. The NovaGuard SA safety system could be available for all geographic markets and commercial supply. Currently, the NovaGuard SA safety system is commercialized with one marketed drug outside of the U.S., and is being evaluated by multiple West pharmaceutical partners.
West is by the side of its healthcare partners from concept to the patient, designing and manufacturing packaging, diagnostic and delivery systems that promote the efficiency, reliability and safety of their products. Every day, West is leading the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched and growing knowledge base of pharmaceutical product testing, development and packaging. Based in Exton, Pa., West supports customers from sales, manufacturing, and research and development locations in North and South America, Europe, Asia and Australia. West's 2013 sales reflect the daily use of approximately 100 million of its components and devices around the world. www.westpharma.com.
West and the diamond logo, By your side for a healthier world™ and NovaGuard™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.